A systematic review of the safety and efficacy of systemic corticosteroids in atopic dermatitis

Systemic corticosteroids are often used to treat atopic dermatitis (AD). However, few studies have assessed the safety and efficacy of systemic corticosteroids in AD. To systematically review the literature on efficacy and safety of systemic corticosteroid use (oral, intramuscular, and intravenous)...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the American Academy of Dermatology 2018-04, Vol.78 (4), p.733-740.e11
Main Authors: Yu, Sherry H., Drucker, Aaron M., Lebwohl, Mark, Silverberg, Jonathan I.
Format: Article
Language:English
Subjects:
adrenal insufficiency
atopic dermatitis
atopic eczema
corticosteroids
eczema
intramuscular
intravenous
oral
rebound flaring
systemic side effects
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Systemic corticosteroids are often used to treat atopic dermatitis (AD). However, few studies have assessed the safety and efficacy of systemic corticosteroids in AD. To systematically review the literature on efficacy and safety of systemic corticosteroid use (oral, intramuscular, and intravenous) in AD. PubMed, Embase, Medline, Scopus, Web of Science, and Cochrane Library were searched. We included systematic reviews, guidelines, and treatment reviews of systemic corticosteroid use among patients of all ages with a diagnosis of AD (52 reviews and 12 studies). There was general consensus in the literature to limit the use of systemic steroids to short courses as a bridge to steroid-sparing therapies. Systemic side effects include growth suppression in children, osteoporosis, osteonecrosis, adrenal insufficiency, Cushing syndrome, hypertension, glucose intolerance, diabetes, gastritis, gastroesophageal reflux, peptic ulcer disease, weight gain, emotional lability, behavioral changes, opportunistic infections, cataracts, glaucoma, myopathy, myalgia, dysaesthesia, pseudotumor cerebri, hyperlipidemia, malignancy, thrombosis, skin atrophy, sleep disturbance, and rebound flaring. Baseline clinical severity, corticosteroid delivery and dose, and treatment response were reported incompletely and heterogeneously across studies. Evidence is not strong enough to determine optimal delivery or duration of systemic corticosteroids in AD.
ISSN:0190-9622
1097-6787
DOI:10.1016/j.jaad.2017.09.074